{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:05:51Z","timestamp":1770894351388,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Addict"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>Synthetic opioids, including fentanyl and fentanyl analogs, account for over 70,000 annual overdose deaths in the United States, but there is limited information examining methods of induction and maintenance outcomes for buprenorphine treatment of patients with opioid use disorder (OUD) using these opioids.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A secondary analysis of results grouped by fentanyl use status was completed for an open\u2010label study with rapid induction of extended\u2010release buprenorphine in the inpatient research unit. Eligible participants received a single 4\u2009mg dose of transmucosal buprenorphine (BUP\u2010TM) followed by an extended\u2010release buprenorphine 300\u2009mg injection ([BUP\u2010XR]) after approximately 1\u2009h. An extension study continued follow\u2010up up to 6 months (6 monthly injections).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among participants with fentanyl\u2010positive urine samples (FEN+; <jats:italic>n<\/jats:italic>\u2009=\u200919), all received BUP\u2010TM, 17 received BUP\u2010XR, 13 elected to receive a second BUP\u2010XR injection, and 10 received all six scheduled injections. Among participants with fentanyl\u2010negative samples (FEN\u2212; <jats:italic>n<\/jats:italic>\u2009=\u20097), all received BUP\u2010TM and BUP\u2010XR, four elected to receive a second injection, and two participants received all six scheduled injections. Induction day clinical opioid withdrawal scale (COWS) scores were similar for FEN+ and FEN\u2212 groups. In the FEN+ group, mean COWS scores fell to below 5 within 24\u2009h of BUP\u2010XR injection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and Conclusions<\/jats:title><jats:p>The treatment of individuals with OUD using fentanyl with a rapid 1\u2010day induction to BUP\u2010XR 300\u2009mg injection is feasible and well\u2010tolerated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Scientific Significance<\/jats:title><jats:p>A prospective trial of participants grouped by fentanyl use status at induction demonstrates comparable patient retention and clinical response following single\u2010day induction of BUP\u2010XR in participants who are FEN+ and FEN\u2212.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajad.13484","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T08:08:38Z","timestamp":1699430918000},"page":"8-14","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Open\u2010label investigation of rapid initiation of extended\u2010release buprenorphine in patients using fentanyl and fentanyl analogs"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9535-7744","authenticated-orcid":false,"given":"John J.","family":"Mariani","sequence":"first","affiliation":[{"name":"Division on Substance Use Disorders New York State Psychiatric Institute New York New York USA"},{"name":"Department of Psychiatry Columbia University Irving Medical Center New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Dobbins","sequence":"additional","affiliation":[{"name":"Global Medicines Development Indivior Inc. Richmond Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Heath","sequence":"additional","affiliation":[{"name":"Global Medicines Development Indivior Inc. Richmond Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Gray","sequence":"additional","affiliation":[{"name":"Global Medicines Development Indivior Inc. Richmond Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Hassman","sequence":"additional","affiliation":[{"name":"Hassman Research Institute CenExel Berlin New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health. In: Quality CfBHSa ed. Vol HHS Publication No. PEP21\u201007\u201001\u2010003. Rockville MD: Substance Abuse and Mental Health Services Administration; 2021."},{"key":"e_1_2_8_3_1","unstructured":"AhmadF RossenL SuttonP. Provisional drug overdose death counts. In: Statistics NCfH; 2022."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.10.016"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90685-W"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2010.12.007"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(93)90152-S"},{"issue":"4","key":"e_1_2_8_8_1","first-page":"848","article-title":"Modulation by mu\u2010opioid agonists of guanosine\u20105\u2032\u2010O\u2010(3\u2010[35S]thio)triphosphate binding to membranes from human neuroblastoma SH\u2010SY5Y cells","volume":"47","author":"Traynor JR","year":"1995","journal-title":"Mol Pharmacol"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1980.138"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.12.005"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.0c00890"},{"key":"e_1_2_8_12_1","first-page":"e265","volume-title":"J Addict Med","author":"Varshneya NB","year":"2021"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2022.2032730"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13394"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.156973"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.6108"},{"key":"e_1_2_8_17_1","unstructured":"DEA.2020 National Drug Threat Assessment;2021."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13135"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13113"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000961"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13069"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.17128"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmab073"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13018"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13193"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.1052"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32259-1"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_2_8_29_1","first-page":"1","article-title":"Open\u2010label, rapid initiation pilot study for extended\u2010release buprenorphine subcutaneous injection","volume":"26","author":"Hassman H","year":"2022","journal-title":"Am J Drug Alcohol Abuse"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2003.10400007"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001202"},{"key":"e_1_2_8_32_1","unstructured":"Providers Clinical Support System Practice\u2010Based Guidelines: Buprenorphine in the Age of Fentanyl.2023. Accessed September 17 2023.https:\/\/pcssnow.org\/wp-content\/uploads\/2023\/05\/PCSS-Fentanyl-Guidance-FINAL-1.pdf"}],"container-title":["The American Journal on Addictions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajad.13484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T16:42:30Z","timestamp":1704472950000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajad.13484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/ajad.13484"],"URL":"https:\/\/doi.org\/10.1111\/ajad.13484","archive":["Portico"],"relation":{},"ISSN":["1055-0496","1521-0391"],"issn-type":[{"value":"1055-0496","type":"print"},{"value":"1521-0391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"assertion":[{"value":"2023-03-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}